AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24214585 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ranitidine (initial dose 50 mg, then every 8 hours for 3 days, followed by 150 mg every 12 hours)
Number of subjects: 89
Study 24214585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole
Number of subjects: 89
Study 24214585 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ranitidine
Number of subjects: 89
Study 20631407 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg dietary phosphorus diet
Number of subjects: 16
Study 20631407 — intervention group
Group type: EXPERIMENTAL
Intervention: lanthanum carbonate 1000 mg three times daily
Number of subjects: 16
Study 20631407 — intervention group
Group type: COMPARATOR
Intervention: 1500 mg dietary phosphorus diet plus placebo
Number of subjects: 16
Study 20095352 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemotherapy history (C group, n = 52)
Number of subjects: 107
Study 20095352 — intervention group
Group type: EXPERIMENTAL
Intervention: No preoperative chemotherapy history (N group, n = 55)
Number of subjects: 107
Study 16441928 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil-based lipid emulsion (OO group)
Number of subjects: 35
Study 16441928 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil-based lipid emulsion (SO group)
Number of subjects: 35
Study 16441928 — intervention group
Group type: COMPARATOR
Intervention: Comparison between OO and SO
Number of subjects: 35
Study 15319104 — intervention group
Group type: COMPARATOR
Intervention: Neutral dorsiflexion position
Number of subjects: 109
Study 15319104 — intervention group
Group type: COMPARATOR
Intervention: Dorsiflexed position
Number of subjects: 109
Study 15319104 — intervention group
Group type: COMPARATOR
Intervention: Plantarflexed position
Number of subjects: 109
Study 10945316 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal mecamylamine 6 mg/24 h
Number of subjects: 12
Study 10945316 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 12
Study 9396102 — intervention group
Group type: EXPERIMENTAL
Intervention: Letters condition
Number of subjects: 177
Study 9396102 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive condition
Number of subjects: 177
Study 9396102 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 177
Study 9396102 — intervention group
Group type: EXPERIMENTAL
Intervention: Hotline use
Number of subjects: 177
Study 8454793 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 standardized quality units (SQ-U) (0.7 microgram Der p I)
Number of subjects: 74
Study 8454793 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 SQ-U (7 micrograms Der p I)
Number of subjects: 74
Study 8454793 — intervention group
Group type: EXPERIMENTAL
Intervention: 300,000 SQ-U (21 micrograms Der p I)
Number of subjects: 74
Study 8454793 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT)
Number of subjects: 74
Study 8454793 — intervention group
Group type: COMPARATOR
Intervention: N/A (control group with no injections)
Number of subjects: 74
Study 8454793 — intervention group
Group type: EXPERIMENTAL
Intervention: N/A (systemic reactions)
Number of subjects: 74
Study 3783150 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet (1,000 kcal per day for six weeks)
Number of subjects: 0
Study 3783150 — intervention group
Group type: COMPARATOR
Intervention: Mixed diet (1,000 kcal per day for six weeks)
Number of subjects: 0
Study 3783150 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative carbohydrate intake
Number of subjects: 0
Study 3783150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of plasma tryptophan to other large neutral amino acids
Number of subjects: 0
Study 30476065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit & Strong! Plus (F&S! Plus)
Number of subjects: 413
Study 30257847 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone pilot/feasibility studies
Number of subjects: 176
Study 30257847 — intervention group
Group type: COMPARATOR
Intervention: External pilot/feasibility studies
Number of subjects: 176
Study 30257847 — intervention group
Group type: COMPARATOR
Intervention: Internal pilot/feasibility studies
Number of subjects: 176
Study 27382674 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatophagoides farina extracts sublingual immunotherapy for 2 years
Number of subjects: 77
Study 27382674 — intervention group
Group type: COMPARATOR
Intervention: Control group (pharmacotherapy)
Number of subjects: 77
Study 26237978 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 120
Study 26237978 — intervention group
Group type: EXPERIMENTAL
Intervention: NSES (Neck-skin electrical stimulation)
Number of subjects: 120
Study 26237978 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + NSES (Combined treatment)
Number of subjects: 120
Study 26237978 — intervention group
Group type: COMPARATOR
Intervention: NSES
Number of subjects: 120
Study 23912267 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina-on-alumina ceramic bearing
Number of subjects: 100
Study 23912267 — intervention group
Group type: COMPARATOR
Intervention: Alumina-on-highly cross-linked polyethylene bearing
Number of subjects: 100
Study 23912267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 21803113 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 3 mg
Number of subjects: 0
Study 21803113 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine 0 mg (placebo)
Number of subjects: 0
Study 21803113 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 6 mg
Number of subjects: 0
Study 19803577 — intervention group
Group type: EXPERIMENTAL
Intervention: Family CBT (FCBT)
Number of subjects: 53
Study 19803577 — intervention group
Group type: COMPARATOR
Intervention: Individual cognitive‐behavioral therapy (ICBT)
Number of subjects: 53
Study 19803577 — intervention group
Group type: COMPARATOR
Intervention: Family-based education/support/attention control (FESA)
Number of subjects: 53
Study 16698473 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTI (temporal clear corneal incision)
Number of subjects: 61
Study 16698473 — intervention group
Group type: EXPERIMENTAL
Intervention: CCOI (on-axis clear corneal incision)
Number of subjects: 61
Study 16698473 — intervention group
Group type: COMPARATOR
Intervention: CCTI and CCOI
Number of subjects: 61
Study 15596155 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions based on the modified reattribution model
Number of subjects: 127
Study 15596155 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific psychosocial primary care (PPC)
Number of subjects: 127
Study 11493293 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed CO2 laser
Number of subjects: 13
Study 11493293 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser
Number of subjects: 13
Study 9404178 — intervention group
Group type: COMPARATOR
Intervention: Caudal epidural block with 0.25% bupivacaine 1 ml.kg‐1 and preservative‐free ketamine 0.5 mg.kg‐1
Number of subjects: 40
Study 9404178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal nerve block with 0.25% bupivacaine 0.5 ml.kg‐1 and infiltration of the wound with 0.25% bupivacaine 0.5 ml.kg‐1
Number of subjects: 40
Study 9404178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal nerve block
Number of subjects: 40
Study 8558350 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete immediate dentures
Number of subjects: 74
Study 8558350 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate overdentures on two lower canines without attachments
Number of subjects: 74
Study 8558350 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate overdentures on two lower canines with Dyna direct magnetic attachments
Number of subjects: 74
Study 2671424 — intervention group
Group type: EXPERIMENTAL
Intervention: NY‐198
Number of subjects: 258
Study 2671424 — intervention group
Group type: COMPARATOR
Intervention: NFLX
Number of subjects: 258
Study 2671424 — intervention group
Group type: EXPERIMENTAL
Intervention: NY‐198-NY‐198
Number of subjects: 258
Study 2671424 — intervention group
Group type: EXPERIMENTAL
Intervention: NFLX-NFLX
Number of subjects: 258
Study 2671424 — intervention group
Group type: EXPERIMENTAL
Intervention: NY‐198-placebo
Number of subjects: 258
Study 2671424 — intervention group
Group type: EXPERIMENTAL
Intervention: NFLX-placebo
Number of subjects: 258
Study 2671424 — intervention group
Group type: COMPARATOR
Intervention: NY‐198 and NFLX
Number of subjects: 258
Study 1053479 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (loop diuretic)
Number of subjects: 0
Study 1053479 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-sparing diuretic added to thiazide or furosemide
Number of subjects: 0
Study 1053479 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics in diuretic doses
Number of subjects: 0
Study 1053479 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide or increased dose of loop diuretic
Number of subjects: 0
Study 30676468 — intervention group
Group type: EXPERIMENTAL
Intervention: IC‐ECG guidance (n = 80)
Number of subjects: 160
Study 30676468 — intervention group
Group type: COMPARATOR
Intervention: Anatomical landmark guidance (n = 80)
Number of subjects: 160
Study 27604568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (subanesthetic dose)
Number of subjects: 26
Study 27604568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 25939111 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape training (23 minutes)
Number of subjects: 265
Study 25939111 — intervention group
Group type: COMPARATOR
Intervention: Six experimental training conditions (including videotape + psychomotor skill training + cognitive rehearsal training)
Number of subjects: 265
Study 23621525 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux metal stent (ARMS)
Number of subjects: 13
Study 22401279 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (3000 IU intramuscular injection on day 5 after oestrus)
Number of subjects: 27
Study 22401279 — intervention group
Group type: COMPARATOR
Intervention: Saline (intramuscular injection on day 5 after oestrus)
Number of subjects: 27
Study 20080961 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum‐formed retainer in the maxilla and bonded canine‐to‐canine retainer in the mandible (group V‐CTC)
Number of subjects: 75
Study 20080961 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum‐formed retainer in the maxilla combined with stripping of the 10 proximal surfaces of the lower mandibular anterior teeth (group V‐S)
Number of subjects: 75
Study 20080961 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated positioner covering the teeth in the maxilla and mandible (group P)
Number of subjects: 75
Study 18001713 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucuna pruriens treatment
Number of subjects: 120
Study 16511633 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed Tracheal Suction System (CTSS) without daily change
Number of subjects: 457
Study 16511633 — intervention group
Group type: COMPARATOR
Intervention: Open Tracheal Suction System (OTSS)
Number of subjects: 457
Study 12555294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Pringle manoeuvre
Number of subjects: 40
Study 12555294 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 11127843 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (long term use)
Number of subjects: 0
Study 11127843 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-receptor antagonists (short term use <6 weeks)
Number of subjects: 0
Study 11127843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dihydralazine
Number of subjects: 0
Study 11127843 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (concurrent with MgSO4)
Number of subjects: 0
Study 11127843 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 9257783 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens from grass and rye pollen (n = 41)
Number of subjects: 87
Study 9257783 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens from grass and rye pollen (n = 22)
Number of subjects: 87
Study 9257783 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 87
Study 8499205 — intervention group
Group type: EXPERIMENTAL
Intervention: Hudson face mask at 4 litre min‐1 (group I)
Number of subjects: 30
Study 8499205 — intervention group
Group type: COMPARATOR
Intervention: Nasal cannulae at 2 litre min‐1 (group II)
Number of subjects: 30
Study 3304473 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP regimen (low doses of adriamycin)
Number of subjects: 0
Study 3304473 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy, radiotherapy, splenectomy, leukapheresis, monoclonal antibodies, immunomodulating agents
Number of subjects: 0
Study 3304473 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 0
Study 31628854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Number of subjects: 0
Study 31628854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 400 mg
Number of subjects: 0
Study 31628854 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (active control)
Number of subjects: 0
Study 31628854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29120908 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopurine treatment (discontinuation rate 22% in accepting group)
Number of subjects: 767
Study 29120908 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopurine treatment (steady-state metabolite levels)
Number of subjects: 767
Study 25072784 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 7447
Study 25072784 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist‐to‐height ratio (WHtR)
Number of subjects: 7447
Study 25072784 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 7447
Study 25072784 — intervention group
Group type: COMPARATOR
Intervention: PREDIMED intervention
Number of subjects: 7447
Study 22385415 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-tramadol combination (diclofenac 100 mg rectal suppository 8 hourly till 24 h + tramadol 75 mg intravenous 6 hourly)
Number of subjects: 204
Study 22385415 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac-acetaminophen combination (diclofenac 100 mg rectal suppository 8 hourly till 24 h + acetaminophen 1 g intravenous 6 hourly)
Number of subjects: 204
Study 22385415 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (diclofenac-tramadol and diclofenac-acetaminophen)
Number of subjects: 204
Study 20820456 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) combined with a coronally advanced flap (CAF)
Number of subjects: 20
Study 20820456 — intervention group
Group type: COMPARATOR
Intervention: Enamel matrix derivative (EMD) combined with a coronally advanced flap (CAF)
Number of subjects: 20
Study 19040171 — intervention group
Group type: EXPERIMENTAL
Intervention: Care coordination programs with nurse-provided patient education (mostly by telephone), average of two contacts per month.
Number of subjects: 0
Study 19040171 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 15727280 — intervention group
Group type: EXPERIMENTAL
Intervention: Website information provided to the experimental group prior to surgery.
Number of subjects: 64
Study 15727280 — intervention group
Group type: COMPARATOR
Intervention: Control group (no website information).
Number of subjects: 64
Study 12845985 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous portal triad clamping
Number of subjects: 35
Study 12845985 — intervention group
Group type: COMPARATOR
Intervention: Intermittent portal triad clamping
Number of subjects: 35
Study 10378323 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (200 IU dalteparin per kilogram body-weight per 24 hours), firm compression bandages, and encouraged walking
Number of subjects: 929
Study 10378323 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression bandages and compression stockings (in ongoing randomized trial)
Number of subjects: 929
Study 8927235 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) 100 micrograms
Number of subjects: 10
Study 8927235 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin fragment (ACTH 4-9) 300 micrograms
Number of subjects: 10
Study 8927235 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 10
Study 8354332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose (5 g)
Number of subjects: 8
Study 8354332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose (15 g)
Number of subjects: 8
Study 8354332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose (30 g)
Number of subjects: 8
Study 8354332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose (35 g)
Number of subjects: 8
Study 8354332 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amino acids (10 g)
Number of subjects: 8
Study 3545108 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole in combination with thyroxine (Group I)
Number of subjects: 30
Study 3545108 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (Group II)
Number of subjects: 30
Study 29626233 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 IU of hCG with 40 μL of culture medium injected into the uterus before embryo transfer
Number of subjects: 180
Study 29626233 — intervention group
Group type: COMPARATOR
Intervention: 40 μL of culture medium infused into the uterus before embryo transfer (sham control)
Number of subjects: 180
Study 29626233 — intervention group
Group type: COMPARATOR
Intervention: No intervention (second control group)
Number of subjects: 180
Study 27809880 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive training (towards positive and away from negative stimuli)
Number of subjects: 126
Study 27809880 — intervention group
Group type: COMPARATOR
Intervention: Sham training (control condition)
Number of subjects: 126
Study 25025247 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 7
Study 25025247 — intervention group
Group type: COMPARATOR
Intervention: Non-gum-chewing control
Number of subjects: 7
Study 22785255 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐interferon‐alpha‐2a (PEG‐IFN)
Number of subjects: 40
Study 20386325 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula+LCP
Number of subjects: 0
Study 20386325 — intervention group
Group type: COMPARATOR
Intervention: Formula
Number of subjects: 0
Study 18672194 — intervention group
Group type: EXPERIMENTAL
Intervention: PIIINP
Number of subjects: 1009
Study 18672194 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-1
Number of subjects: 1009
Study 18672194 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-18
Number of subjects: 1009
Study 16165009 — intervention group
Group type: EXPERIMENTAL
Intervention: Women to Women computer-based intervention
Number of subjects: 63
Study 12742805 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril and indapamide)
Number of subjects: 6105
Study 12742805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study 11106133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 10 mg
Number of subjects: 243
Study 11106133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 243
Study 11106133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 11106133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (both doses)
Number of subjects: 243
Study 8873505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nicotine spray
Number of subjects: 19
Study 8873505 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 19
Study 1855281 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dexamethasone (i.v.)
Number of subjects: 31
Study 1855281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 7049340 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin and linoleic acid supplements
Number of subjects: 22
Study 7049340 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 22
Study 31453760 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural directionality mode
Number of subjects: 13
Study 31453760 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive directionality mode
Number of subjects: 13
Study 31453760 — intervention group
Group type: COMPARATOR
Intervention: Omnidirectional mode
Number of subjects: 13
Study 28260596 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic hysterectomy (RALH)
Number of subjects: 360
Study 28260596 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH)
Number of subjects: 360
Study 27050347 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide/timolol (BT)
Number of subjects: 73
Study 27050347 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide/timolol (DT)
Number of subjects: 73
Study 25079862 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 489
Study 25079862 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest HbA1c tertile
Number of subjects: 489
Study 25079862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest HbA1c levels
Number of subjects: 489
Study 22849964 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 0
Study 22849964 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 0
Study 19039808 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (8-week programme, 2-hour sessions)
Number of subjects: 203
Study 19039808 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 203
Study 17451577 — intervention group
Group type: EXPERIMENTAL
Intervention: Stacked double pulses (single-pass treatment)
Number of subjects: 11
Study 17451577 — intervention group
Group type: COMPARATOR
Intervention: Double-pass treatment of single pulses
Number of subjects: 11